Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Cabaletta Bio (NASDAQ:CABAFree Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright also issued estimates for Cabaletta Bio’s FY2028 earnings at $4.16 EPS.

A number of other brokerages also recently issued reports on CABA. Cantor Fitzgerald reiterated an overweight rating and set a $50.00 price objective on shares of Cabaletta Bio in a research note on Friday, April 5th. Citigroup lifted their target price on Cabaletta Bio from $26.00 to $30.00 and gave the stock a buy rating in a report on Thursday, April 4th. Jefferies Financial Group began coverage on Cabaletta Bio in a research note on Monday, February 5th. They set a buy rating and a $36.00 price target for the company. Finally, Wells Fargo & Company lifted their price objective on Cabaletta Bio from $34.00 to $35.00 and gave the stock an overweight rating in a research note on Friday, March 22nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Cabaletta Bio currently has an average rating of Buy and a consensus price target of $34.33.

View Our Latest Research Report on Cabaletta Bio

Cabaletta Bio Stock Performance

Shares of CABA stock opened at $12.35 on Thursday. Cabaletta Bio has a 12-month low of $9.02 and a 12-month high of $26.35. The firm’s 50 day moving average is $15.26 and its 200 day moving average is $18.66.

Cabaletta Bio (NASDAQ:CABAGet Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). On average, analysts predict that Cabaletta Bio will post -2.07 earnings per share for the current year.

Institutional Investors Weigh In On Cabaletta Bio

Institutional investors have recently modified their holdings of the stock. Amalgamated Bank raised its holdings in Cabaletta Bio by 24.7% during the 3rd quarter. Amalgamated Bank now owns 4,648 shares of the company’s stock valued at $71,000 after buying an additional 922 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Cabaletta Bio by 65.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,623 shares of the company’s stock worth $60,000 after acquiring an additional 1,042 shares during the last quarter. Macroview Investment Management LLC purchased a new position in shares of Cabaletta Bio during the 4th quarter worth about $26,000. California State Teachers Retirement System boosted its stake in shares of Cabaletta Bio by 6.0% during the 1st quarter. California State Teachers Retirement System now owns 30,428 shares of the company’s stock worth $519,000 after purchasing an additional 1,711 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Cabaletta Bio by 65.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,206 shares of the company’s stock valued at $140,000 after purchasing an additional 3,244 shares during the last quarter.

About Cabaletta Bio

(Get Free Report)

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.

Featured Articles

Analyst Recommendations for Cabaletta Bio (NASDAQ:CABA)

Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.